Mediators and receptors in the resolution of inflammation
Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics
Resolvins and protectins
The hepoxilins and some analogues
Sphingolipids in inflammation
Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease
Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents
Protease-activated receptors and prostaglandins in inflammatory lung disease
Protective mechanisms of activated protein C in severe inflammatory disorders
Proteases and antiproteases in chronic neutrophilic lung disease – relevance to drug discovery
Lipid mediator interplay
Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress
Preventive and therapeutic anti-inflammatory properties of the sesquiterpene α-humulene in experimental airways allergic inflammation
Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases
Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats
Regulation by FK506 and rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle
Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death
Tanshinone I enhances learning and memory, and ameliorates memory impairment in mice via the extracellular signal-regulated kinase signalling pathway
Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2
Reversal of temperature-induced conformational changes in the amyloid-beta peptide, Aβ40, by the β-sheet breaker peptides 16–23 and 17–24